Tampa, FL (PRWEB) May 04, 2013 World Stem Cells Clinic in Cancun is pleased to announce the appointment of Dr. Ernesto Gutierrez to the position of President of their medical lab and treatment center. Dr. Gutierrez brings experience and intensity to his new position at World Stem Cells Clinic and promises he and his team of experts will provide the best medical care available in the world to improve their patients quality of life. Dr. Ernesto Gutierrez is an extensively educated physician. He is a graduate from the Universidad Anhuac Norte, School of Medicine in Mexico City and additionally holds a Post-Graduate Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica, Guadalajara, Mexico. He holds active membership of both the Mexican College of Aesthetic and Anti-Aging Medicine and the Age Management Medicine Group. Dr. Gutierrez has spent considerable time in additional training in the US, with rotations in both Florida and Nevada for two specialty organizations and is certified in Age Management Medicine by the Cenegenics Education and Research Foundation part of Cenegenics Medical Institute in Las Vegas, Nevada. His bilingual English and Spanish skills, both in medical and conversational applications, are excellent. Dr. … Continue reading →

May 1, 2013 A small device implanted in the brain has accurately predicted epilepsy seizures in humans in a world-first study led by Professor Mark Cook, Chair of Medicine at the University of Melbourne and Director of Neurology at St Vincent's Hospital. "Knowing when a seizure might happen could dramatically improve the quality of life and independence of people with epilepsy," said Professor Cook, whose research was today published in the medical journal Lancet Neurology. Professor Cook and his team, with Professors Terry O'Brien and Sam Berkovic, worked with researchers at Seattle-based company, NeuroVista, who developed a device which could be implanted between the skull and brain surface to monitor long-term electrical signals in the brain (EEG data). They worked together to develop a second device implanted under the chest, which transmitted electrodes recorded in the brain to a hand-held device, providing a series of lights warning patients of the high (red), moderate (white), or low (blue), likelihood of having a seizure in the hours ahead. The two year study included 15 people with epilepsy aged between 20 and 62 years, who experienced between two and 12 seizures per month and had not had their seizures controlled with existing treatments. … Continue reading →

Non-Invasive Neurostimulation System, Well-Received in Europe , Now Available in Canada for Adults and Children 9 years and older LOS ANGELES , May 2, 2013 /CNW/ - NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada . The license covers the use of the Monarch eTNS System for treatment of drug-resistant epilepsy (DRE), major depressive disorder (MDD), and treatment-resistant depression. (Photo: http://photos.prnewswire.com/prnh/20130502/LA06314) The Monarch, CE Mark approved in the European Union in 2012, but not yet approved in the United States (US), is now available to patients in Canada . Drug resistant epilepsy (DRE) is a serious medical disorder, and affects approximately 30% of all patients with epilepsy. Major depressive disorder is a prevalent condition, affecting up to 16% of the population at some point during their lives. The Health Canada approval was supported by years of safety and efficacy data generated in Phase I and Phase II clinical trials in the US, in which the therapy was shown to substantially reduce seizure frequency and significantly improve mood. Results from a Phase II Randomized Controlled Trial of eTNS … Continue reading →